Compare AbbVie Inc (ABBV) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? AbbVie Inc trades at $249.52 (market cap $438.19B), while First Trust NASDAQ 100 Technology Index Fund trades at $315.63. The key difference: AbbVie Inc pays a 2.79% dividend while First Trust NASDAQ 100 Technology Index Fund pays none. Which is the better fit depends on your goals.
| ABBV | QTEC | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $263.58 | $335.74 |
52-Week Low | $197.38 | $207.03 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
QTEC trades at $316.59, up 1.7% with a bullish technical signal from moving averages. The ETF, tracking NASDAQ-100 technology stocks, lacks disclosed P/E and P/S ratios. A small dividend of $0.03 is scheduled for June 2026, with support at $313 and resistance at $319.
Outlook remains positive due to strong technical momentum, though overbought RSI signals caution. Risks include tech sector volatility and reliance on broad market trends. Analyst coverage highlights its role for diversified tech exposure without specific ratings available.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
